Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in...

Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC ( Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA )

CaboNivo shows sustained long-term benefits for survival and tumour progression...

Prof Camillo Porta - University of Bari, Bari, Italy,

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta - University of Bari, Bari, Italy, )

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide...

Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone ( Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA )

Enfortumab vedotin in combination with pembrolizumab shows improved survival...

Prof Thomas Powles - Barts Cancer Institute, London, England

Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC ( Prof Thomas Powles - Barts Cancer Institute, London, England )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Prostate cancer

Dr Alison Tree - Institute of Cancer Research, London, UK

Prostate cancer ( Dr Alison Tree - Institute of Cancer Research, London, UK )

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Pembrolizumab shows improvement in overall survival for clear cell renal cell...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar...

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona...

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Study shows association between tumour KIM-1 gene (HAVCR1) expression and...

Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece

Study shows association between tumour KIM-1 gene (HAVCR1) expression and immune infiltrates in RCC ( Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece )

Guiding metastasis-directed therapy with different PET/CT radiotracers affects...

Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy

Guiding metastasis-directed therapy with different PET/CT radiotracers affects distant disease control in HSPC patients ( Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy )

Outcomes of radium-223 and SABR versus SABR for oligometastatic prostate cancers

Dr Ana Kiess - Johns Hopkins University, Baltimore, USA

Outcomes of radium-223 and SABR versus SABR for oligometastatic prostate cancers ( Dr Ana Kiess - Johns Hopkins University, Baltimore, USA )

More from ecancer